id	url	estudio_clinico	fase_estudio_clinico	tipo_celula	pais	n_participantes	fecha_inicio	fecha_conclusion
1	https://hpscreg.eu/browse/trial/202	Stereotactic Intracerebral Injection of IPSC-DAPs in Patients with Parkinson's Disease	Phase 1	dopaminergic neuron	China	12	2025-05-15	2026-09-30
2	https://hpscreg.eu/browse/trial/206	A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants with Spinal Cord Injury (DOSED)	Phase 1	oligodendrocyte precursor cell	United States	10	2025-04-30	2037-04-27
3	https://hpscreg.eu/browse/trial/199	A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) (CLARICO)	Phases 1/2	photoreceptor cell	United States	54	2025-03-10	2030-10-31
4	https://hpscreg.eu/browse/trial/201	A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease	Phases 1/2	mesenchymal stem cell	China	30	2025-03-01	2028-09-01
5	https://hpscreg.eu/browse/trial/200	Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo	Early Phase 1		China	29	2025-02-05	2026-11-17
6	https://hpscreg.eu/browse/trial/205	The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/​Refractory Acute T-lymphoblastic Leukemia	Early Phase 1	natural killer cell		9	2025-02-01	2026-10-31
7	https://hpscreg.eu/browse/trial/203	Exploratory Study on the Treatment of Moderate to Severe Acute Respiratory Distress Syndrome in Children with Exosomes Derived from Induced Pluripotent Stem Cells (iPSC-Exo)	Phase 2		China	28	2025-01-01	2026-12-31
8	https://hpscreg.eu/browse/trial/204	iPSC-Derived CTL Therapy for Cervical Cancer: Phase I clinical trial (iPSC-Derived CTL Therapy for Cervical Cancer: Phase I clini	Phase 1	cytotoxic T cell	Japan	12	2024-12-27	2028-12-31
9	https://hpscreg.eu/browse/trial/197	An open-label, single-center, first-in-human study to evaluate the safety, tolerability and activity of autologous human induced pluripotent stem cell derived endothelial cells (hiPSC-ECs) in patients with peripheral artery disease	Not applicable	endothelial cell	South Korea	10	2024-12-20	2028-08-13
10	https://hpscreg.eu/browse/trial/191	Ph I Trial of Cell Based Therapy for DMD	Phase 1			8	2024-12-16	2027-03-03
11	https://hpscreg.eu/browse/trial/190	Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons	Phase 1	dopaminergic neuron	United States	8	2024-12-01	2028-12-31
12	https://hpscreg.eu/browse/trial/192	Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia (iNK-r/r AML)	Early Phase 1	natural killer cell		10	2024-11-25	2026-11-24
13	https://hpscreg.eu/browse/trial/195	A Phase 1/​2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)	Phase 2	interneuron	United States	10	2024-11-14	2040-07-15
14	https://hpscreg.eu/browse/trial/196	A PHASE IIB, RANDOMIZED, ASSESSOR-MASKED, MULTICENTER CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF SUBRETINAL IMPLANTATION OF THE CPCB-RPE1 IMPLANT IN SUBJECTS WITH ADVANCED, DRY AMD (GEOGRAPHIC ATROPHY) (PATCH-AMD)	Phase 2	retinal pigment epithelial cell	United States	24	2024-10-01	2040-12-31
15	https://hpscreg.eu/browse/trial/194	The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease	Phase 1	dopaminergic neuron	China	6	2024-08-23	2027-03-01
16	https://hpscreg.eu/browse/trial/169	Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease	Phase 1	dopaminergic neuron	United States	6	2024-08-07	2027-12-31
17	https://hpscreg.eu/browse/trial/159	A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (CALiPSO-1) (CALiPSO-1)	Phase 1	natural killer cell	United States	48	2024-08-02	2028-08-31
18	https://hpscreg.eu/browse/trial/136	Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia	Phase 1	natural killer cell	United States		2024-07-15	2024-08-21
19	https://hpscreg.eu/browse/trial/164	Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	Phase 1	natural killer cell	United States	33	2024-07-11	2029-06-30
20	https://hpscreg.eu/browse/trial/182	Clinical study to evaluate the safety and efficacy of human-induced pluripotent stem cell-derived platelets in patients with acute leukemia undergoing chemotherapy-induced thrombocytopenia	Other	platelet	China	3	2024-07-02	2029-07-01
21	https://hpscreg.eu/browse/trial/189	Follow-up study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting	Phase 2	cardiac muscle cell	Japan	10	2024-06-13	
22	https://hpscreg.eu/browse/trial/181	Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II) CT1-DAP001	Phase 1	dopaminergic neuron	United States	7	2024-06-01	2028-05-01
23	https://hpscreg.eu/browse/trial/176	The Effect of GD-iExo-003 in Acute Ischemic Stroke ExoCURE	Phase 1		China	29	2024-05-27	2025-08-30
24	https://hpscreg.eu/browse/trial/167	Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia	Phase 1	natural killer cell	China	24	2024-04-30	2026-08-31
25	https://hpscreg.eu/browse/trial/168	Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration	Phases 1/2	retinal pigment epithelial cell	India	54	2024-04-06	2030-12-31
26	https://hpscreg.eu/browse/trial/161	FT819 in Moderate to Severe Active Systemic Lupus Erythematosus	Phase 1	T cell	United States	32	2024-03-28	2042-09-30
27	https://hpscreg.eu/browse/trial/198	Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS) (iPSC-MNP)	Not applicable	neural stem cell	China	3	2024-03-13	2025-05-13
28	https://hpscreg.eu/browse/trial/165	A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD	Not applicable	mesenchymal stem cell	China	12	2024-02-10	2027-03-02
29	https://hpscreg.eu/browse/trial/157	A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor	Not applicable	natural killer cell	China	50	2024-02-01	2030-03-01
30	https://hpscreg.eu/browse/trial/149	A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA (NCR100)	Phase 1	mesenchymal stem cell	China	12	2024-01-25	2025-05-31
31	https://hpscreg.eu/browse/trial/162	Phase 1/​2a Study of ANPD001 in Parkinson Disease (ASPERO)	Phase 1	dopaminergic neuron	United States	9	2024-01-23	2030-04-30
32	https://hpscreg.eu/browse/trial/193	The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease	Phases 1/2	dopaminergic neuron	China	40	2024-01-17	2029-07-31
33	https://hpscreg.eu/browse/trial/156	FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors	Phase 1	T cell	United States	351	2024-01-05	2044-05-01
34	https://hpscreg.eu/browse/trial/28	Retinal Pigment Epithelium Safety Study For Patients In B4711001	Long term follow up	retinal pigment epithelial cell	United Kingdom	10	2024-01-01	2033-05-30
35	https://hpscreg.eu/browse/trial/151	Safety and Feasibility of DopaCell transplantation in patients with Parkinson's disease	Phase 1	dopaminergic neuron	Iran	4	2023-12-22	
36	https://hpscreg.eu/browse/trial/153	A single-center, phase 1/2a clinical trial to evaluate the safety, maximum tolerated dose, and exploratory efficacy of MR-MC-01 treatment in patients with underactive bladder	Phases 1/2	mesenchymal stem cell	South Korea	33	2023-12-15	
37	https://hpscreg.eu/browse/trial/186	Phase II clinical trial of CAStem cell injection in the treatment of acute graft-versus-host disease	Phase 2		China	18	2023-12-01	2024-11-30
38	https://hpscreg.eu/browse/trial/155	Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for dilated cardiomyopathy	Phase 1	cardiac muscle cell	Japan	4	2023-11-25	
39	https://hpscreg.eu/browse/trial/152	A Clinical Trial of Parkinson's Disease Treatment by hiPSCs Derived Dopaminergic Neural Precursor Cells	Not applicable	dopaminergic neuron	China	3	2023-11-23	2025-12-22
40	https://hpscreg.eu/browse/trial/148	FT522 With Rituximab in Relapsed/​Refractory B-Cell Lymphoma (FT522-101)	Phase 1	natural killer cell	United States	166	2023-11-16	2044-06-30
41	https://hpscreg.eu/browse/trial/160	A Safety and Tolerability Study of Human Forebrain Neural Progenitor Cells Injection (hNPC01) in Subjects With Chronic Ischemic Stroke	Phase 1	neural stem cell	China	21	2023-11-09	2025-12-30
42	https://hpscreg.eu/browse/trial/175	Natural Killer (NK) Cells (XS005) Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)	Phases 1/2	natural killer cell		30	2023-10-29	2025-12-29
43	https://hpscreg.eu/browse/trial/154	A Phase I/II Study of Evaluate the Safety and Efficacy of HLCR011 in Patients with Retinal Pigment Epithelium Tear	Phases 1/2	retinal pigment epithelial cell	Japan	21	2023-10-18	
44	https://hpscreg.eu/browse/trial/185	Efficacy and safety of CAStem cell injection in the treatment of acute exacerbation of interstitial lung disease (AE-ILD)	Phase 2		China	45	2023-09-21	2025-12-31
45	https://hpscreg.eu/browse/trial/180	Long Term Follow-up of Patients With Parkinson's Disease Who Had Administered of A9-DPC in SB-PD-001 Study	Long term follow up	dopaminergic neuron	South Korea	12	2023-09-14	2029-06-29
46	https://hpscreg.eu/browse/trial/163	Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure	Phases 1/2	cardiac muscle cell	China	36	2023-09-05	2025-03-05
47	https://hpscreg.eu/browse/trial/133	A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD	Phase 2	Mesenchymal Stem Cell	Australia	60	2023-08-31	2026-12-31
48	https://hpscreg.eu/browse/trial/183	Safety and Efficacy of MCA-derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients: The Nereid Study*	Phases 1/2	mesenchymal stem cell	Netherlands	16	2023-07-01	
49	https://hpscreg.eu/browse/trial/142	An exploratory clinical study of islet-like cell transplantation differentiated from autologous induced pluripotent stem cells for the treatmen of type 1 diabetes	Alternative regulatory mechanism	progenitor cell of endocrine pancreas	China	3	2023-06-11	2023-12-01
50	https://hpscreg.eu/browse/trial/178	Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy	Early Phase 1			34	2023-06-05	2025-11-13
51	https://hpscreg.eu/browse/trial/138	Treatment of Non-ischemic Cardiomyopathies by Intravenous Extracellular Vesicles of Cardiovascular Progenitor Cells (SECRET-HF)	Phase 1	cardioblast	France	12	2023-05-31	2026-07-15
52	https://hpscreg.eu/browse/trial/141	Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01	Long term follow up	dopaminergic neuron	United States	12	2023-05-16	2027-09-30
53	https://hpscreg.eu/browse/trial/139	A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes	Phases 1/2	progenitor cell of endocrine pancreas	United States	17	2023-05-16	2026-05-31
54	https://hpscreg.eu/browse/trial/140	Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients	Phases 1/2	dopaminergic neuron	South Korea		2023-05-09	2026-02-07
55	https://hpscreg.eu/browse/trial/150	Observational study one year after transplantation of iPS cell-derived neural precursor/stem cells for spinal cord injury	Long term follow up	neural stem cell	Japan	4	2023-05-01	2035-03-31
56	https://hpscreg.eu/browse/trial/158	Combination therapy of iPS-NKT cell and DC/Gal (Combination therapy of iPS-NKT cell and DC/Gal)	Phase 1	natural killer cell	Japan	6	2023-05-01	
57	https://hpscreg.eu/browse/trial/137	MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	Phase 1	natural killer cell	United States	33	2023-04-28	2028-09-30
58	https://hpscreg.eu/browse/trial/177	Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis	Early Phase 1		China	20	2023-04-12	2025-06-30
59	https://hpscreg.eu/browse/trial/132	A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration	Phase 2	retinal pigment epithelial cell		60	2023-03-24	2029-04-11
60	https://hpscreg.eu/browse/trial/166	Safety and Efficacy of Pluripotent Stem Cell-derived Mesenchymal Stem Cell Exosome (PSC-MSC-Exo) Eye Drops Treatment for Dry Eye Diseases Post Refractive Surgery and Associated With Blepharospasm	Phases 1/2	mesenchymal stem cell	China	12	2023-03-01	2025-02-01
61	https://hpscreg.eu/browse/trial/135	Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease	Phase 1	cardiac muscle cell	United States		2023-02-03	2029-02-28
62	https://hpscreg.eu/browse/trial/126	A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)	Phase 1	natural killer cell	United States	75	2023-01-24	2027-08-31
63	https://hpscreg.eu/browse/trial/62	IPS Differentiated Cardiomyocytes Vein Transplantation for Chronic Heart Failure (IDCVTCHF)	Phase 2/3	cardiac muscle cell	China	3	2022-12-31	2024-12-31
64	https://hpscreg.eu/browse/trial/146	Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia	Phase 1	natural killer cell	China	19	2022-12-24	2025-12-24
65	https://hpscreg.eu/browse/trial/179	FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma	Phase 1		United States		2022-12-01	2023-05-01
66	https://hpscreg.eu/browse/trial/127	A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease (STEM-PD)	Phase 1	dopaminergic neuron		8	2022-11-30	2027-11-30
67	https://hpscreg.eu/browse/trial/147	Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia	Phase 1	natural killer cell	China	18	2022-10-28	2025-10-21
68	https://hpscreg.eu/browse/trial/125	Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure	Early Phase 1	cardiac muscle cell	China	32	2022-10-09	2025-07-31
69	https://hpscreg.eu/browse/trial/184	Safety and Tolerability of IMMUNA(IMM01-STEM) in Patients With Muscle Atrophy Related to Knee Osteoarthritis	Phase 1		United States	13	2022-09-13	2024-11-08
70	https://hpscreg.eu/browse/trial/119	Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration	Phase 1	retinal pigment epithelial cell	China	10	2022-08-01	2026-12-31
71	https://hpscreg.eu/browse/trial/116	Treating Heart Failure With hiPSC-CMs	Phases 1/2	cardiac muscle cell		20	2022-06-30	2025-12-30
72	https://hpscreg.eu/browse/trial/120	Clinical trial of human (allogeneic) iPS cell-derived cardiomyocytes sheet for ischemic cardiomyopathy (Follow-up trial)	Long term follow up	cardiac muscle cell	Japan	10	2022-06-22	
73	https://hpscreg.eu/browse/trial/110	FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy	Phases 1/2	interneuron	United States	58	2022-06-16	2042-02-28
74	https://hpscreg.eu/browse/trial/121	Evaluation of knee function and safety after treatment of knee articular cartilage damage with iPS-cell-derived cartilage	Long term follow up	cartilage tissue	Japan	4	2022-06-16	
75	https://hpscreg.eu/browse/trial/187	A study on the effectiveness and safety of CAStem cell injection in the treatment of acute respiratory distress syndrome	Phase 2		China	72	2022-06-10	2024-03-10
76	https://hpscreg.eu/browse/trial/123	FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1	natural killer cell	United States	5	2022-05-31	2023-08-11
77	https://hpscreg.eu/browse/trial/131	A prospective observational study of Induced Pluripoteint Stem Cell-derived Cardiac Spheres transplantation EXTENDed Follow-up	Long term follow up	cardiac muscle cell	Japan	3	2022-04-01	2029-03-31
78	https://hpscreg.eu/browse/trial/114	Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction (HECTOR)	Phase 1	cardiac muscle cell	United States	18	2022-03-22	2025-10-31
79	https://hpscreg.eu/browse/trial/124	Clinical Research of allogeneic iPSC-RPE cell strip transplantation for RPE impaired disease (CR of aiPSC-RPE CSt transplantation forRID)	Phases 1/2	retinal pigment epithelial cell	Japan	50	2022-02-22	
80	https://hpscreg.eu/browse/trial/188	The safety, tolerability, and preliminary efficacy of CAStem injection intravenously injected into the knee for meniscus injury in Chinese subjects	Phases 1/2		China	24	2022-02-21	2023-06-21
81	https://hpscreg.eu/browse/trial/115	An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D	Phase 1	progenitor cell of endocrine pancreas	United States	7	2022-01-24	2023-01-19
82	https://hpscreg.eu/browse/trial/143	Clinical study on the safety and efficacy of human embryonic stem cell-derived retinal pigment epithelial cells transplantation for the treatment of macular hole of high myopia	Other	retinal pigment epithelial cell	China	12	2022-01-15	2022-12-31
83	https://hpscreg.eu/browse/trial/130	Safety, Tolerability and Efficacy of CYP-006TK in Adults With Diabetic Foot Ulcers	Phase 1	mesenchymal stem cell	Australia	30	2022-01-04	2024-09-30
84	https://hpscreg.eu/browse/trial/122	A Clinical Research on the Safety of Hepatocytes Therapy Generated from Human Embryonic Stem Cells for Patients with Acute or Acute-on-Chronic Liver Failure	Other	hepatocyte	China	10	2022-01-01	2024-10-31
85	https://hpscreg.eu/browse/trial/84	Regenerative medicine for spinal cord injury at subacute stage using human induced pluripotent stem cell-derived neural stem/progenitor cells	Not applicable	neural stem cell	Japan	4	2021-12-07	
86	https://hpscreg.eu/browse/trial/118	FT576 in Subjects With Multiple Myeloma	Phase 1	natural killer cell	United States	168	2021-11-24	2040-02-29
87	https://hpscreg.eu/browse/trial/145	Natural Killer (NK) Cell Therapy for B-Cell Malignancies	Phase 1	natural killer cell	China	24	2021-11-04	2024-12-31
88	https://hpscreg.eu/browse/trial/104	FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia	Phase 1	natural killer cell	United States	50	2021-11-03	2025-12-15
89	https://hpscreg.eu/browse/trial/106	FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1	natural killer cell	United States	16	2021-10-15	2023-08-11
90	https://hpscreg.eu/browse/trial/39	A Study Of Implantation Of Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration	Phase 1	retinal pigment epithelial cell	United Kingdom	9	2021-10-14	2024-06-14
91	https://hpscreg.eu/browse/trial/9	Treating Heart Failure With hPSC-CMs (HEAL-CHF)	Phases 1/2	cardiac muscle cell	China	15	2021-10-08	2024-10-30
92	https://hpscreg.eu/browse/trial/89	phase 1/2a clinical study to evaluate the safety and exploratory efficacy for PSA-NCAM (+) NPC	Phases 1/2	neural progenitor cell	South Korea	5	2021-09-23	2030-09-30
93	https://hpscreg.eu/browse/trial/108	Treating Congestive HF With hiPSC-CMs Through Endocardial Injection	Phase 1	cardiac muscle cell	China	20	2021-09-21	2023-07-31
94	https://hpscreg.eu/browse/trial/105	A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis	Phase 1	mesenchymal stem cell	United States	30	2021-08-31	2027-12-31
95	https://hpscreg.eu/browse/trial/109	MEG-002: Exploratory clinical study in thrombocytopenic patients	Phases 1/2	platelet	Japan	10	2021-08-19	
96	https://hpscreg.eu/browse/trial/100	FT819 in Subjects With B-cell Malignancies	Phase 1	T cell	United States	396	2021-07-26	2039-09-30
97	https://hpscreg.eu/browse/trial/107	iPS cell-derived corneal endothelial cell substitutes for bullous keratopathy	Not applicable	corneal endothelial cell	Japan	3	2021-07-15	
98	https://hpscreg.eu/browse/trial/113	A phase I/II study of human induced Pluripotent Stem (iPS) cell-derived cardiomyocyte spheroids in patients with severe heart failure, secondary to ischemic heart disease, undergoing coronary artery bypass grafting (LAPiS Study)	Phases 1/2	cardiac muscle cell	Japan	10	2021-06-23	
99	https://hpscreg.eu/browse/trial/111	A phase 1 clinical trial of intraperitoneal administration of iCAR-ILC/N101 for ovarian clear cell carcinoma	Phase 1	natural killer cell	Japan	18	2021-05-10	
100	https://hpscreg.eu/browse/trial/102	Phase 1 Study To Assess the Safety and Tolerability of Human Embryonic Stem Cell-Derived Midbrain Dopamine Neuron	Phase 1	dopaminergic neuron	United States	12	2021-05-03	2024-06-10
101	https://hpscreg.eu/browse/trial/92	FT516 and IL2 With Enoblituzumab for Ovarian Cancer	Phase 1	natural killer cell	United States	3	2021-04-02	2022-01-01
102	https://hpscreg.eu/browse/trial/112	A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes	Phases 1/2	progenitor cell of endocrine pancreas	United States	17	2021-03-29	2028-01-31
103	https://hpscreg.eu/browse/trial/86	Stem cell therapy in knee osteoarthritis	Phase 3	mesenchymal stem cell	Australia	440	2021-03-15	2025-12-31
104	https://hpscreg.eu/browse/trial/90	Clinical Research of allogeneic iPSC-RPE cell suspension transplantation for RPE impaired disease (CR of aiPSC-RPE CS transplantation forRID)	Phases 1/2	retinal pigment epithelial cell	Japan	50	2021-03-01	
105	https://hpscreg.eu/browse/trial/91	A Clinical Trial to Evaluate the Effects of Autologous induced Pluripotent Stem Cell-Derived Natural Killer Cells in Personalized Treatment of Patients with Advanced Metastatic Breast Cancer	Phase 1	natural killer cell	Iran	32	2021-02-18	
106	https://hpscreg.eu/browse/trial/103	A Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects With Chronic Ischemic Subcortical Stroke (ISS)	Phases 1/2	neural stem cell	United States	30	2021-01-04	2025-05-31
107	https://hpscreg.eu/browse/trial/72	Development of treatment of knee articular cartilage damage with iPS-cell-derived cartilage. (Development of treatment of knee articular cartilage damage with iPS-cell-derived cartilage.)	Not applicable	cartilage tissue	Japan	4	2020-11-11	
108	https://hpscreg.eu/browse/trial/88	Safety study of induced pluripoteint stem cell-derived cardiac spheres transplantation (IPSCS study)	Other	cardiac muscle cell	Japan	3	2020-11-09	
109	https://hpscreg.eu/browse/trial/85	Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis	Phase 1	mesenchymal stem cell	South Korea	3	2020-10-20	2022-12-31
110	https://hpscreg.eu/browse/trial/98	FT538 in Subjects With Advanced Hematologic Malignancies	Phase 1	natural killer cell	United States	42	2020-10-17	2023-08-08
111	https://hpscreg.eu/browse/trial/83	Safety Study of allogenic hiPSC-retinas in Retinitis Pigmentosa	Phase 1	retina	Japan	2	2020-10-05	
112	https://hpscreg.eu/browse/trial/76	Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration	Phases 1/2	retinal pigment epithelial cell	United States	20	2020-09-23	2029-05-31
113	https://hpscreg.eu/browse/trial/101	FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL	Phase 1	natural killer cell	United States	3	2020-09-22	2024-02-02
114	https://hpscreg.eu/browse/trial/79	A Phase I study of iPS-NKT cell intra-arterial infusion therapy in patients with recurrent or advanced head and neck cancer	Phase 1	natural killer cell	Japan	9	2020-09-11	
115	https://hpscreg.eu/browse/trial/99	FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1	natural killer cell	United States	12	2020-09-07	2023-08-11
116	https://hpscreg.eu/browse/trial/75	The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (MEND)	Phases 1/2	mesenchymal stem cell	Australia	14	2020-08-24	2022-05-18
117	https://hpscreg.eu/browse/trial/74	Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia	Phase 1	natural killer cell	United States	5	2020-05-14	2022-02-18
118	https://hpscreg.eu/browse/trial/60	Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa	Phase 1	retinal pigment epithelial cell	China	10	2020-05-01	2021-12-31
119	https://hpscreg.eu/browse/trial/78	Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia (COVID-19)	Other	mesenchymal stem cell	China	20	2020-03-20	2021-03-19
120	https://hpscreg.eu/browse/trial/80	FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies	Phase 1	natural killer cell	United States	98	2020-03-19	2023-09-27
121	https://hpscreg.eu/browse/trial/87	Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure (BioVAT-HF)	Phases 1/2	cardiac muscle cell	Germany	53	2020-02-03	2024-10-31
122	https://hpscreg.eu/browse/trial/73	Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS	Phases 1/2	mesenchymal stem cell	China	9	2020-01-27	2020-12-31
123	https://hpscreg.eu/browse/trial/71	Clinical study of human (allogeneic) iPS cell-derived cardiomyocyte sheet for ischemic cardiomyopathy	Phase 1	cardiac muscle cell	Japan	10	2020-01-10	
124	https://hpscreg.eu/browse/trial/82	Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions	Phase 1	mesenchymal stem cell	China	32	2020-01-01	2022-12-31
125	https://hpscreg.eu/browse/trial/134	Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy	Phase 1	cardiac muscle cell	Japan		2019-12-02	2023-05-30
126	https://hpscreg.eu/browse/trial/63	FT516 in Subjects With Advanced Hematologic Malignancies	Phase 1	natural killer cell	United States	72	2019-10-04	2023-10-23
127	https://hpscreg.eu/browse/trial/174	Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy	Long term follow up	natural killer cell	United States	2	2019-10-04	2020-04-09
128	https://hpscreg.eu/browse/trial/61	Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation	Phases 1/2	dendritic cell, human	France	7	2019-08-19	2026-12-15
129	https://hpscreg.eu/browse/trial/53	Clinical trial of human (allogeneic) induced pluripotent stem cell-derived cardiomyocyte sheet for severe cardiomyopathy	Phases 1/2	cardiac muscle cell	Japan	3	2019-08-11	2022-06-30
130	https://hpscreg.eu/browse/trial/117	A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus (VC01-103)	Phases 1/2	progenitor cell of endocrine pancreas	United States	31	2019-06-25	2019-11-19
131	https://hpscreg.eu/browse/trial/64	Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy	Other	natural killer cell	United States	20	2019-06-11	2023-08-11
132	https://hpscreg.eu/browse/trial/59	First-in-human clinical research of iPS derived corneal epithelial cell sheet transplantation for patients with limbal stem-cell deficiency	Phase 1	corneal epithelial cell	Japan	4	2019-05-23	2021-12-13
133	https://hpscreg.eu/browse/trial/81	iPSC-derived platelet transfusion trial1 (iPLAT1)	Phase 1	platelet	Japan	1	2019-05-14	
134	https://hpscreg.eu/browse/trial/48	Mesenchymal Stem Cells (MSCs) - Like Cell Transplantation in Women With Primary Ovarian Insufficiency (MSCLCTWPOI)	Phase 1	mesenchymal stem cell	China	28	2019-04-03	2021-12-31
135	https://hpscreg.eu/browse/trial/68	A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke	Other	neural stem cell	China	12	2019-03-01	2019-03-31
136	https://hpscreg.eu/browse/trial/52	FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors	Phase 1	natural killer cell	United States	37	2019-02-15	2022-11-15
137	https://hpscreg.eu/browse/trial/66	A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem Cells	Other	neural stem cell		10	2019-02-01	2021-02-01
138	https://hpscreg.eu/browse/trial/46	Safety Observation on hESC Derived MSC Like Cell for the Meniscus Injury	Phase 1	mesenchymal stem cell	China	18	2019-01-04	2020-09-30
139	https://hpscreg.eu/browse/trial/69	A Study of Autologous Induced Islet Body With Type 1 Diabetes	Other	islet of Langerhans		20	2019-01-01	2021-01-31
140	https://hpscreg.eu/browse/trial/67	iHSCs With the Gene Correction of HBB Intervent Subjests With β-thalassemia Mutations	Other	hematopoietic stem cell	China	12	2019-01-01	2021-01-31
141	https://hpscreg.eu/browse/trial/70	A Clinical Study of iEPC Intervent Subjects With Cerebral Hemorrhagic Stroke	Other	Endothelial Progenitor Cell		12	2018-12-01	2020-12-31
142	https://hpscreg.eu/browse/trial/33	Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases	Phases 1/2	retinal pigment epithelial cell	China	10	2018-10-01	
143	https://hpscreg.eu/browse/trial/54	Kyoto Trial to Evaluate the Safety and Efficacy of iPSC-derived dopaminergic progenitors in the treatment of Parkinson's Disease	Phases 1/2	dopaminergic neuron	Japan	7	2018-08-01	2023-12-31
144	https://hpscreg.eu/browse/trial/8	Kyoto Trial to Evaluate the Safety and Efficacy of Tacrolimus in the iPSC-based Therapy for Parkinson's Disease	Phase 3	dopaminergic neuron	Japan	7	2018-08-01	2023-12-31
145	https://hpscreg.eu/browse/trial/12	A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration Secondary to Dry Age-related Macular Degeneration	Phase 1	retinal pigment epithelial cell	United States	18	2018-07-13	2025-12-31
146	https://hpscreg.eu/browse/trial/6	AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer	Phase 1	dendritic cell, human		8	2018-06-01	2022-08-08
147	https://hpscreg.eu/browse/trial/77	Clinical study of HAES transplantation in patients with neonatal onset urea cycle disorder	Phases 1/2	hepatocyte	Japan	5	2018-04-30	2022-09-30
148	https://hpscreg.eu/browse/trial/45	A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phases 1/2	astrocyte	Israel	16	2018-04-12	2020-06-22
149	https://hpscreg.eu/browse/trial/24	A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy	Phases 1/2	retinal pigment epithelial cell	United States	36	2018-01-08	2029-03-31
150	https://hpscreg.eu/browse/trial/32	Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Clinical-grade Human Embryonic Stem Cells	Phases 1/2	retinal pigment epithelial cell	China	10	2017-09-06	2020-12-31
151	https://hpscreg.eu/browse/trial/43	A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness	Phases 1/2	progenitor cell of endocrine pancreas	United States	49	2017-07-06	2023-10-19
152	https://hpscreg.eu/browse/trial/5	A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus	Phase 1	progenitor cell of endocrine pancreas	United States	3	2017-07-05	2018-02-15
153	https://hpscreg.eu/browse/trial/34	Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease	Phases 1/2	dopaminergic neuron	China	50	2017-05-01	2020-12-31
154	https://hpscreg.eu/browse/trial/7	A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	Phase 1	mesenchymal stem cell	Australia	16	2017-03-01	2020-06-30
155	https://hpscreg.eu/browse/trial/51	A Study of transplantation of allogenic induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell suspension in subjects with neovascular age related macular degeneration	Other	retinal pigment epithelial cell	Japan	5	2017-02-06	2021-09-20
156	https://hpscreg.eu/browse/trial/29	One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™	Long term follow up	progenitor cell of endocrine pancreas	United States	200	2016-11-07	2023-11-30
157	https://hpscreg.eu/browse/trial/58	A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease	Phase 1	neural stem cell	Australia	12	2016-07-01	2020-06-30
158	https://hpscreg.eu/browse/trial/57	The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD	Phase 1	mesenchymal stem cell		3	2016-05-01	2019-04-30
159	https://hpscreg.eu/browse/trial/40	Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD	Phases 1/2	retinal pigment epithelial cell	United States	16	2016-02-16	2023-06-30
160	https://hpscreg.eu/browse/trial/37	The clinical trial of human embryonic stem cell derived epithelial cells transplantation in the treatment of severe ocular surface diseases	Alternative regulatory mechanism	corneal epithelial cell	China	20	2015-10-01	
161	https://hpscreg.eu/browse/trial/55	Clinical study of subretinal transplantation of clinical human embryo stem cell derived retinal pigment epitheliums in treatment of retinitis pigmento diseases	Other	retinal pigment epithelial cell	China	10	2015-09-20	2017-12-20
162	https://hpscreg.eu/browse/trial/10	Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD (PORTRAY)	Phase 2	retinal pigment epithelial cell	United States		2015-08-24	2017-05-05
163	https://hpscreg.eu/browse/trial/38	Stem Cell Therapy for Outer Retinal Degenerations	Phases 1/2	retinal pigment epithelial cell	Brazil		2015-08-01	2019-06-30
164	https://hpscreg.eu/browse/trial/44	Clinical study of subretinal transplantation of human embryo stem cell derived retinal pigment epitheliums in treatment of macular degeneration diseases	Phases 1/2	retinal pigment epithelial cell	China	10	2015-05-01	2019-12-31
165	https://hpscreg.eu/browse/trial/30	Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration	Phases 1/2	retinal pigment epithelial cell		24	2015-04-01	2025-07-01
166	https://hpscreg.eu/browse/trial/36	Dose Escalation Study of AST-OPC1 in Spinal Cord Injury	Phases 1/2	oligodendrocyte precursor cell		25	2015-03-01	2018-12-31
167	https://hpscreg.eu/browse/trial/65	Thalassemia Treatment Based on the Stem Cell Technology	Not applicable	hematopoietic stem cell	China	2	2015-01-01	2017-12-31
168	https://hpscreg.eu/browse/trial/42	A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus	Phases 1/2	progenitor cell of endocrine pancreas	United States	19	2014-09-01	2017-12-31
169	https://hpscreg.eu/browse/trial/2	A Study of transplantation of autologous induced pluripotent stem cell (iPSC) derived retinal pigment epithelium (RPE) cell sheet in subjects with exudative age related macular degeneration	Other	retinal pigment epithelial cell	Japan	2	2013-10-02	2019-02-28
170	https://hpscreg.eu/browse/trial/1	Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure (ESCORT)	Phase 1	cardioblast	France	10	2013-05-27	2018-03-22
171	https://hpscreg.eu/browse/trial/41	Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration	Phases 1/2	retinal pigment epithelial cell	United States		2013-03-01	2016-06-30
172	https://hpscreg.eu/browse/trial/25	Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD	Long term follow up	retinal pigment epithelial cell	United States	11	2013-02-25	2019-08-19
173	https://hpscreg.eu/browse/trial/26	A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)	Long term follow up	retinal pigment epithelial cell	United States	12	2013-01-16	2019-10-02
174	https://hpscreg.eu/browse/trial/31	A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration (AMD)	Phases 1/2	retinal pigment epithelial cell		12	2012-09-01	2020-06-30
175	https://hpscreg.eu/browse/trial/4	Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy (SMD)	Phase 1	retinal pigment epithelial cell	South Korea	3	2012-09-01	2015-06-30
176	https://hpscreg.eu/browse/trial/27	Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients	Long term follow up	retinal pigment epithelial cell	United States	13	2012-07-11	2019-06-21
177	https://hpscreg.eu/browse/trial/14	Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)	Phases 1/2	retinal pigment epithelial cell	United States	12	2011-12-13	2015-09-30
178	https://hpscreg.eu/browse/trial/11	Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy	Phases 1/2	retinal pigment epithelial cell	United States	13	2011-06-16	2015-08-10
179	https://hpscreg.eu/browse/trial/13	Safety and Tolerability of Sub-retinal Transplantation of hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD)	Phases 1/2	retinal pigment epithelial cell	United States	13	2011-06-09	2015-08-19
180	https://hpscreg.eu/browse/trial/3	Safety Study of GRNOPC1 in Spinal Cord Injury	Phase 1	oligodendrocyte precursor cell	United States	5	2010-10-01	2013-07-31
